Johnson & Johnson (NYSE:JNJ) issued an update on its FY16 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $6.68-6.73 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.69. The company issued revenue guidance of $71.5-72.2 billion, compared to the consensus revenue estimate of $72.14 billion.

Johnson & Johnson (NYSE:JNJ) opened at 118.49 on Tuesday. The stock has a market cap of $324.17 billion, a P/E ratio of 22.08 and a beta of 0.62. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The company has a 50 day moving average of $118.71 and a 200-day moving average of $117.56.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.65 by $0.03. The firm earned $17.80 billion during the quarter, compared to the consensus estimate of $17.71 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.49 earnings per share. Equities analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current year.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

A number of brokerages have commented on JNJ. Vetr upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $124.21 target price for the company in a report on Monday, August 22nd. Leerink Swann reiterated an outperform rating and issued a $140.00 target price (up from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Zacks Investment Research downgraded shares of Johnson & Johnson from a buy rating to a hold rating in a report on Tuesday, September 20th. RBC Capital Markets reiterated an outperform rating and issued a $133.00 target price (up from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Finally, Jefferies Group boosted their target price on shares of Johnson & Johnson from $109.00 to $113.00 and gave the stock a hold rating in a report on Thursday, July 14th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $120.20.

In other news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Banced Corp increased its position in Johnson & Johnson by 10.9% in the second quarter. Banced Corp now owns 7,644 shares of the company’s stock valued at $714,000 after buying an additional 754 shares in the last quarter. American Century Companies Inc. increased its position in Johnson & Johnson by 24.5% in the second quarter. American Century Companies Inc. now owns 7,061,430 shares of the company’s stock valued at $856,551,000 after buying an additional 1,388,010 shares in the last quarter. Wedge Capital Management L L P NC increased its position in Johnson & Johnson by 12.9% in the second quarter. Wedge Capital Management L L P NC now owns 422,349 shares of the company’s stock valued at $51,231,000 after buying an additional 48,208 shares in the last quarter. Exane Derivatives increased its position in Johnson & Johnson by 305.4% in the second quarter. Exane Derivatives now owns 2,027 shares of the company’s stock valued at $246,000 after buying an additional 1,527 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its position in Johnson & Johnson by 5.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 291,845 shares of the company’s stock valued at $35,401,000 after buying an additional 14,552 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.